

*receptor associated protein*  
selected from the group consisting of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin.

2. (amended) A preparation according to claim 1, characterized in that said pro-protein is derived from a biological material selected from the group consisting of human plasma, a plasma fraction and a cell culture supernatant.

3. (amended) A preparation according to claim 1, characterized in that it is provided as a set comprising

- a) said pro-protein of blood coagulation and
- b) said receptor binding competitor.

4. (amended) A preparation according to claim 1, characterized in that said pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture of aprotinin and tPA.

5. (amended) A preparation according to claim 1, characterized in that said pro-protein of blood coagulation is vWF and said receptor binding competitor is a mixture of aprotinin and tPA.

7. (amended) A method of treating a patient suffering from phenotypic coagulation factor deficiency, comprising the step of administering a composition according to claim 1 to said patient.

8. (amended) The method according to claim 7, further comprising the step of selecting a patient who is vWF deficient.

Please cancel claim 9 without prejudice or disclaimer of the subject matter contained therein.

10. (amended) The method of claim 7, wherein said receptor binding competitor is a mixture of aprotinin and tPA.

11.(amended) The method of claim 7, wherein said pro-protein is blood coagulation factor VIII.

Please cancel claim 12 without prejudice or disclaimer of the subject matter contained therein.

### CONCLUSION

In view of the foregoing, Applicants believe that all claims now pending in this application are in condition for examination. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned attorney at (949) 250-6828.

Respectfully Submitted,



Janice Guthrie  
Registration No. 35,170

Baxter Healthcare Corporation  
PO Box 15210  
Irvine, Ca 92623-5210  
Telephone: (949) 250-6828  
Facsimile: (949) 474-6330

09831680-010900